Skye bioscience, inc.SKYE.US Overview

US StockHealthcare

(No presentation for SKYE)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

SKYE Overall Performance

SKYE AI Analysis & Strategy

SKYE Recent Performance

-1.88%

Skye bioscience, inc.

0.81%

Avg of Sector

-1.14%

S&P500

SKYE PowerScanner

SKYE Key Information

SKYE Valuation Metrics

SKYE Earnings Table

SKYE Profile

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.